Clean Energy Research Foundation


Contact Us
New Technology
Electricity Storage Technology
Electricity Storage Methods table
Worldwide Methane Reduction Project
Materials R&D
Nanotube adhesive sales
Nanotube Adhesive Press release & photo
Nanotube Adhesive SEM
Carbon nanotubes on sale

The human immunodeficiency virus was discovered more than thirty years ago and since then a cure for AIDS has eluded researchers. A viable vaccine that can prevent the spread of that disease has also eluded medical science despite huge amounts of research. The insidious nature of the HIV virus causes the problem. The virus destroys functions of the immune system that protect the body from viral pathogens. The immune system is so weakened that viral antigens in vaccines don't evoke a strong enough immune response to stop the HIV virus particles from infecting lymphocytes. Dozens of vaccines have been tried and none work.

Gene therapies have also been tested- most of them in animals and a few in humans. They can reduce the viral load somewhat but they cannot cure AIDS or prevent it. Current gene therapies don’t prevent transmission of the virus to uninfected partners either. Gene therapies are not vaccines- they are therapies using vectors that insert DNA into a person's cells. That causes the DNA to be incorporated into the genetic machinery in the nucleus of lymphocytes to transform them. The DNA endows them with extra genes that kill the HIV virus or that prevent the infection of lymphocytes and other immune system cells by blocking their entry via the CCR5 receptors. CCR5 is the chemokine receptor which HIV uses as a coreceptor to gain entry into lymphocytes and macrophages.

None of those gene therapies has produced a cure of the disease. Vulvox is working on a new kind of genetic therapy that has the potential of curing AIDS. We do not claim to have a cure now, but we have reason to think that our new type of gene therapy will be able to cure that disease instead of keeping patients dependent on a cocktail of protease inhibitors and AZT that causes adverse side effects. Vulvox wants joint research and development partnerships and both public and private funding to test our theories and to perfect our gene therapy in animals and humans.

Corporate and academic R&D partners and investors should contact Neil Farbstein President of Vulvox Nanobiotechnology Corporation at